Autoimmune disease companies develop therapies, diagnostics and research technologies for conditions in which the immune system attacks the body’s own cells and tissues. Their work spans disease detection, immune modulation and the development of more targeted treatments.
This category includes companies working on:
Browse 68 UK autoimmune disease companies below.
CRO specialising in oncology, inflammation and respiratory disease models
Axis Bioservices is a preclinical contract research organisation providing bespoke in vitro and in vivo study services for pharmaceutical, biotechnology and academic clients. Specialist capabilities span oncology tumour models, inflammatory disease models including rheumatoid arthritis and pulmonary fibrosis, and…
UK affiliate of global family-owned biopharmaceutical company
Boehringer Ingelheim is a global family-owned biopharmaceutical company founded in 1885. Its Bracknell headquarters houses functions spanning research and development, regulatory affairs, pharmacovigilance, medical affairs, and commercial operations across its human pharma and animal health divisions. It operates…
Immunomodulatory therapeutics for chronic autoimmune and inflammatory diseases
Kherion Technology is a biotechnology company developing immunomodulatory treatments for chronic autoimmune and inflammatory diseases. Its lead preclinical programme investigates a proprietary therapeutic composition intended to reduce chronic inflammation without broadly suppressing immune activity. A granted US…
Human biospecimen and disease-state plasma supplier
Logical Biological is a UK supplier of human biological materials including disease-state and normal-donor serum, plasma, swabs, tissues, PBMCs, and biofluids to IVD manufacturers and life science researchers worldwide. The company sources specimens through a global network of donor centres and blood banks across five…
Preclinical and clinical CRO specialising in biomarker services
Epistem is a contract research organisation providing preclinical and clinical research services to pharmaceutical and biotechnology companies. Its capabilities span in vivo and in vitro preclinical models across oncology, gastrointestinal disease, dermatology, and autoimmune indications, alongside GCLP-accredited…
AI-powered microbiome and phage therapy platform for gut disorders
GutSee Health is a biotechnology company developing precision microbiome therapies for gut disorders including irritable bowel syndrome and inflammatory bowel disease. Its AI discovery platform integrates multi-omics and microbiome data to identify molecular disease signatures and therapeutic targets. A parallel…
Immunometabolism-targeting small molecules for autoimmune disease
Sitryx Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics that modulate immune cell metabolism to achieve disease remission in autoimmune and inflammatory conditions. The company's approach targets novel metabolic enzymes within immune cells, with lead programmes in…
TYK2/JAK1 inhibitor advancing towards Phase 2 psoriasis trials
Sareum is a clinical-stage biotechnology company developing small-molecule kinase inhibitors for autoimmune diseases and cancer. Its lead oral TYK2/JAK1 inhibitor, SDC-1801, completed Phase 1 testing in healthy volunteers and is being prepared for a Phase 2 study in psoriasis. Dosing in its Phase 2-enabling toxicology…
Diagnostic reagents, allergy testing products and contract diagnostics manufacturing
Bio-Diagnostics is a manufacturer of diagnostic products and provider of contract services for the in vitro diagnostics industry. Its own range covers reagents and tests for infectious disease, autoimmunity and immunohistochemistry, alongside an extensive portfolio of allergens and accessories for patch and skin prick…
Topical peptide therapeutics targeting inflammatory skin disease
Carocell Bio is a pre-clinical stage biotechnology company developing proprietary peptide-based therapeutics for inflammatory diseases. Its pipeline centres on topical formulations that inhibit mitogen-activated protein kinase (MAPK/p38), a key regulator of the inflammatory cascade. Lead programmes target atopic…
Immunometabolism drugs for autoimmune and inflammatory diseases
Istesso is a drug discovery and development company working in immunometabolism, developing oral small molecule therapies that reprogram cellular metabolism to treat autoimmune and inflammatory conditions. Its lead candidate is a first-in-class metabolic reprogramming agent for rheumatoid arthritis with a dual…
GPR35 inhibitors for gastrointestinal cancer and inflammatory bowel disease
ThirtyFiveBio is a drug discovery company developing first-in-class small molecule inhibitors of GPR35, a genetically validated G protein-coupled receptor implicated in gastrointestinal disease. The company's approach targets GPR35 antagonism to prevent epithelial cell damage and dysfunction in the gut wall,…
Antibody therapeutics for inflammatory and autoimmune disease
MabGalaxy develops antibody therapeutics for inflammatory and autoimmune diseases, with scientific operations linked to Cambridge's Babraham Research Campus. Its discovery approach combines immune-system biology with artificial intelligence to support antibody design and selection. The company aims to shorten the…
Gut microbiome tests predicting biologic drug response in IBD
AlphaBiomics is a precision medicine company developing diagnostics that analyse the gut microbiome to guide treatment decisions. Its lead test uses a stool sample collected at home and machine learning analysis of microbial sequencing data to predict which patients with inflammatory bowel disease are likely to…
Steroid-free dermatology formulations and investigational GL-1 platform
Gran Lab is a Queen's University Belfast spin-out developing biochemical formulations for inflammatory and reactive skin conditions. Its investigational GL-1 topical platform is being developed as a non-steroidal approach to psoriasis and related dermatoses, with laboratory studies ongoing and clinical trials in…
AI-driven neuroimaging analytics for clinical trials
Queen Square Analytics is a UCL spin-out providing advanced neuroimaging data analytics for neurological clinical trials. The company applies machine learning to MRI data for patient stratification, treatment response prediction, and imaging protocol design, with a primary focus on multiple sclerosis and…
CAR T cell therapies for blood cancer and autoimmune disease
Autolus Therapeutics is a London-based commercial-stage biopharma developing next-generation programmed T cell therapies. Its lead product AUCATZYL (obecabtagene autoleucel) received FDA approval in November 2024 and MHRA conditional marketing authorisation in 2025 for relapsed or refractory B-cell acute lymphoblastic…
Global biopharma focused on neurology and rare disease therapeutics
Biogen is a global biopharma company and one of the world's first biotechnology firms. The UK and Ireland headquarters in Maidenhead employs approximately 250 people across clinical operations, regulatory affairs, drug safety, and medical affairs. The company develops and commercialises therapies for neurological,…
Blood glycomic biomarkers for chronic inflammatory disease detection and monitoring
Avenna is a biotechnology company developing blood-based glycomic biomarkers for chronic inflammatory diseases. Its tests analyse the sugar structures attached to blood proteins to measure chronic inflammation separately from short-term acute inflammation, supporting early detection, disease monitoring and…
Antibody therapies targeting severe autoimmune diseases
argenx UK Ltd is the UK commercial subsidiary of argenx SE, a global immunology company developing antibody-based therapies for severe autoimmune diseases. The company markets VYVGART (efgartigimod), the first approved FcRn blocker in the UK, indicated for generalised myasthenia gravis and chronic inflammatory…